Direct Oral Anticoagulants in Cirrhotic Patients: Current Evidence and Clinical Observations

<table class="fixed-width table-group" id="tab2"><tr><td><table class="table"><colgroup><col style="width:15.08em"/><col style="width:16.78em"/><col style="width:9.27em"/></colgroup><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td class="align_left"><b>Child-Pugh class A</b></td><td class="align_center"><b>Child-Pugh class B</b></td><td class="align_center"><b>Child-Pugh class C</b></td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td class="align_left">Dabigatran (no dose adjustment)</td><td class="align_center">Use with caution (no dose adjustment)</td><td class="align_center">Not recommended</td></tr><tr><td class="align_left">Apixaban (no dose adjustment)</td><td class="align_center">Use with caution (no dose adjustment)</td><td class="align_center">Not recommended</td></tr><tr><td class="align_left">Edoxaban (no dose adjustment)</td><td class="align_center">Not recommended</td><td class="align_center">Not recommended</td></tr><tr><td class="align_left">Rivaroxaban (no dose adjustment)</td><td class="align_center">Not recommended</td><td class="align_center">Not recommended</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>FDA recommendation for DOACs usage in liver disease according to Child-Pugh class.</div>

Canadian Journal of Gastroenterology and Hepatology

tab2

Table 2

Table 2: Direct Oral Anticoagulants in Cirrhotic Patients: Current Evidence and Clinical Observations 